Atria Investments Inc Has $15.61 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Atria Investments Inc boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 4.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 95,809 shares of the company's stock after buying an additional 3,941 shares during the period. Atria Investments Inc's holdings in Zoetis were worth $15,610,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Smithfield Trust Co lifted its position in Zoetis by 3.3% in the 4th quarter. Smithfield Trust Co now owns 2,164 shares of the company's stock worth $352,000 after buying an additional 70 shares in the last quarter. Crew Capital Management Ltd. boosted its position in Zoetis by 7.6% during the fourth quarter. Crew Capital Management Ltd. now owns 6,064 shares of the company's stock valued at $988,000 after purchasing an additional 429 shares during the last quarter. Jag Capital Management LLC increased its position in Zoetis by 1.6% in the 4th quarter. Jag Capital Management LLC now owns 14,153 shares of the company's stock worth $2,306,000 after purchasing an additional 223 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its stake in shares of Zoetis by 19.0% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 3,081 shares of the company's stock worth $500,000 after purchasing an additional 491 shares in the last quarter. Finally, Bahl & Gaynor Inc. grew its stake in shares of Zoetis by 2.9% in the 4th quarter. Bahl & Gaynor Inc. now owns 162,808 shares of the company's stock valued at $26,526,000 after buying an additional 4,522 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ZTS shares. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Morgan Stanley cut their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. Finally, Piper Sandler boosted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $215.90.

Zoetis Stock Performance

ZTS stock traded down $2.94 during trading on Wednesday, reaching $166.96. 3,667,422 shares of the stock were exchanged, compared to its average volume of 3,280,360. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $74.76 billion, a P/E ratio of 30.52, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The stock has a 50 day simple moving average of $166.57 and a 200-day simple moving average of $176.99.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.